Adecto Pharmaceuticals, Inc

Takeda Pharmaceuticals USA, based in Cambridge, MA, is a global pharmaceutical company dedicated to creating better health for people and a brighter future for the world. With a focus on research and development, Takeda strives to transform lives through innovative medicines in areas such as gastrointestinal and inflammation, rare diseases, oncology, neuroscience, plasma-derived therapies, and vaccines. Committed to sustainability and corporate responsibility, Takeda emphasizes access to medicines, ethical practices, and transparency in governance. Through collaboration with diverse colleagues and a patient-centered approach, Takeda continues to advance science and technology to improve healthcare outcomes worldwide. Generated from the website

Oxeia Biopharmaceuticals Inc is a Boston-based company focused on developing innovative solutions for concussion treatment. The organization is dedicated to advancing scientific understanding and finding effective remedies for concussion-related symptoms. With a commitment to addressing the complexities of brain health, Oxeia aims to alleviate the suffering experienced by individuals affected by concussions. Their work reflects a deep understanding of the delicate nature of the brain and the urgent need for effective medical interventions. Generated from the website

Energesis Pharmaceuticals, Inc., located in Boston, MA, is at the forefront of developing innovative therapeutics aimed at achieving effective and sustainable weight loss for individuals struggling with obesity. Their unique approach focuses on increasing energy expenditure through the enhancement of brown adipose tissue (BAT), setting them apart from traditional appetite suppressants. The company's advanced drug candidates promote the recruitment of new brown fat cells from stem progenitor cells, thereby facilitating significant fat loss without impacting lean muscle mass. By harnessing the natural physiological properties of BAT, Energesis aims to address critical unmet needs in obesity treatment while offering synergistic benefits when used alongside existing GLP-1 agents. Generated from the website